Annals of surgical oncology · 2026
HMGB1, An Autophagy-Associated Gene, as a Novel Non-Invasive Diagnostic Biomarker: Clinicopathologic Correlation in Urinary Bladder Carcinoma Patients.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Data Sahil, Trivedi Sameer, Singh Yashasvi, Kumar Ujwal, Kumar Lalit, Shankhwar S N, Srivastava Aviral, Kumar Anil, Kar Amrita Ghosh, Singh Rajesh, Zarekar Rupesh
Аннотация
BACKGROUND: Urinary bladder cancer (UBC) is a leading cause of cancer-related morbidity and mortality worldwide, but current diagnostic methods are invasive and prone to false-negatives. This study aimed to evaluate the diagnostic and prognostic value of HMGB1 protein expression in urothelial carcinoma of the bladder using three distinct methods (serum ELISA, tissue IHC, and mRNA expression) via reverse transcription polymerase chain reaction (RT-PCR) and establishing their correlation.
METHODS: This single-center prospective observational study enrolled adults planned for transurethral resection of bladder tumor (TURBT) from March 2023 to April 2025 at Banaras Hindu University, India. The study enrolled 64 UBC patients and 21 control subject. For analysis, 5 ml of blood and cystoscopic guided tumor tissue were retrieved from UBC patients undergoing TURBT and normal bladder urothelium, and 5 mL blood was retrieved from noncancerous subjects (controls) undergoing cystoscopy for various reasons. Clinicopathologic features including tumor stage (T), grade, risk group, and imaging data also were analyzed with respect to their correlation with HMGB1 expression.
RESULTS: Levels of HMGB1 were significantly elevated in the UBC patients compared with the control patients (serum ELISA [p < 0.001], mRNA [p = 0.002], IHC [p = 0.013]). Expression of HMGB1 correlated significantly with tumor stage (T) and grade, with higher levels observed in muscle-invasive bladder cancer (MIBC) than in non-muscle-invasive bladder cancer (NMIBC). Notably, HMGB1 expression was highest in very-high-risk NMIBC patients. However, correlations with age, sex, MRI-VIRADS score, tumor size, and number of growths were statistically insignificant.
CONCLUSIONS: Elevated levels of HMGB1 correlated with advanced tumor stage, high grade, and MIBC, suggesting its utility in early detection and risk stratification, making it a non-invasive diagnostic and prognostic biomarker for UBC.
METHODS: This single-center prospective observational study enrolled adults planned for transurethral resection of bladder tumor (TURBT) from March 2023 to April 2025 at Banaras Hindu University, India. The study enrolled 64 UBC patients and 21 control subject. For analysis, 5 ml of blood and cystoscopic guided tumor tissue were retrieved from UBC patients undergoing TURBT and normal bladder urothelium, and 5 mL blood was retrieved from noncancerous subjects (controls) undergoing cystoscopy for various reasons. Clinicopathologic features including tumor stage (T), grade, risk group, and imaging data also were analyzed with respect to their correlation with HMGB1 expression.
RESULTS: Levels of HMGB1 were significantly elevated in the UBC patients compared with the control patients (serum ELISA [p < 0.001], mRNA [p = 0.002], IHC [p = 0.013]). Expression of HMGB1 correlated significantly with tumor stage (T) and grade, with higher levels observed in muscle-invasive bladder cancer (MIBC) than in non-muscle-invasive bladder cancer (NMIBC). Notably, HMGB1 expression was highest in very-high-risk NMIBC patients. However, correlations with age, sex, MRI-VIRADS score, tumor size, and number of growths were statistically insignificant.
CONCLUSIONS: Elevated levels of HMGB1 correlated with advanced tumor stage, high grade, and MIBC, suggesting its utility in early detection and risk stratification, making it a non-invasive diagnostic and prognostic biomarker for UBC.